CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

Angioimmunoblastic T-cell Lymphoma Clinical Trial

Official title:

Early Clinical Study on Increasing Dose and Open Label of T Cell Injection Targeting CD7 Autologous Chimeric Antigen Receptor in the Treatment of Relapsed / Refractory CD7 Positive Hemolymph System Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04480788
• Other study ID #: PG-CART-07-001
• Status: Recruiting
• Phase: Phase 1
• Start date: November 24, 2020
• Est. completion date: August 31, 2022

Study information

• Verified date: January 2021
• Source: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
• Contact: Mingzhi Zhang, Doctor
• Phone: +8613838565629
• Email: mingzhi_zhang[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase I was a single arm, open label, dose increasing study to explore the safety, tolerance and Cytodynamic characteristics of the drug, and to preliminarily observe the efficacy of the study drug in relapsed / refractory CD7 Positive hematolymph system malignant tumor patients, so as to explore the clinical applicable dose of phase II. Since the activity and toxicity of cellular drugs (long-term survival drugs) do not have obvious dose dependence, and the increase of their dose may be accompanied by the increase of toxicity, rather than necessary for therapeutic effect, it is not necessarily suitable to recommend the effective dose according to the maximum tolerable dose (MTD). Therefore, this study will be based on the safety data, as well as the preliminary efficacy, efficacy and drug The end point of pharmacokinetics (ORR, the content of CD7 Positive Cells, the expansion and duration of car-t cells) were comprehensively considered to determine the recommended dose for phase II clinical trial.Main research purposes Objective to evaluate the safety and tolerability of T cell injection targeting CD7 autologous chimeric antigen receptor in the treatment of relapsed / refractory CD7 Positive hematological and lymphoid malignancies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: August 31, 2022
• Est. primary completion date: August 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years to 70 Years

Eligibility

Inclusion Criteria:

• The age ranged from 7 to 70 years (including the cut-off value), regardless of gender
• The expected survival time was more than 6 weeks
• ECOG score 0-1
• Malignant lymphoma (including but not limited to acute T-lymphoblastic leukemia / lymphoma; extramedullary NK / T-cell lymphoma, nasal type; peripheral T-cell lymphoma, nonspecific; vascular immunoblastic T-cell lymphoma; intestinal disease associated T-cell lymphomas; anaplastic large cell lymphoma (ALK -); T-cell lymphoblastic leukemia)
• When screening, hematological malignancies with CD7 Positive confirmed by bone marrow examination or tumor pathology with positive rate of CD7 = 30%, meeting one of the

following conditions:

1. At least two chemotherapy regimens failed or did not achieve complete remission or relapse;

2. Patients who relapsed after stem cell transplantation were not affected by other treatment methods;

• For peripheral blood involved acute T-lymphoblastic leukemia / lymphoma and NK / T-cell lymphoma, patients with TCR rearrangement were detected by ngs
• The liver and kidney function, heart and lung function meet the following

requirements:

1. Creatinine = 1.5 ULN;

2. LVEF = 45%;

3. Blood oxygen saturation > 91%;

4. The total bilirubin = 2 × ULN; ALT and AST = 2.5 × ULN; the abnormal ALT and AST caused by diseases (such as liver infiltration or bile duct obstruction) can be relaxed to = 5 × ULN;

• Understand the experiment and have signed the informed consent

Exclusion Criteria:

• Those who need immunosuppressant;
• For intestinal disease-related T-cell lymphoma, patients with intestinal ulcer or hematochezia were examined by colonoscopy;
• In addition to cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical operation, and breast ductal carcinoma in situ after radical operation;
• The patients with positive HBsAg or HBcAb and HBV DNA titer in peripheral blood were not within the normal reference value; those with positive anti HCV antibody and positive HCV RNA in peripheral blood; those with HIV antibody positive and cytomegalovirus DNA positive Syphilis was positive;
• Severe heart disease: including but not limited to unstable angina pectoris, myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification = III), severe arrhythmia;
• Unstable systemic diseases judged by researchers: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;
• Within 7 days before screening, there were active or uncontrollable infections requiring systemic treatment (except for mild genitourinary system infection and upper respiratory tract infection);
• Pregnant or lactating women, female subjects planning pregnancy within 1 year after cell reinfusion or male subjects whose partners plan to conceive within 1 year after cell reinfusion;
• Patients who had received car-t therapy or other gene modified cell therapy before screening;
• Subjects who were receiving systemic steroid therapy or were receiving systemic steroid therapy for 7 days were excluded;
• Participated in other clinical studies within 3 months before screening;
• There was evidence of central nervous system invasion during screening;
• According to the judgment of the researchers, it does not conform to the condition of cell preparation;
• Other researchers think it is not suitable to be included in the study.

Related Conditions & MeSH terms

• Anaplastic Large Cell Lymphoma, ALK-negative
• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-Associated T-Cell Lymphoma
• Extramedullary NK-T-cell Lymphoma, Nasal Type
• Leukemia
• Leukemia, Lymphoid
• Lymphoma
• Lymphoma, Large-Cell, Anaplastic
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Peripheral
• Peripheral T-cell Lymphoma, Nonspecific
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• T Lymphoblastic Leukemia/Lymphoma
• T-cell Lymphoblastic Leukemia

Intervention

Biological:
• T cell injection targeting CD7 chimeric antigen receptor
Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation

Locations

Country	Name	City	State
China	First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
PersonGen BioTherapeutics (Suzhou) Co., Ltd.	The First Affiliated Hospital of Zhengzhou University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicity (DLT)		Up to 2 years
Secondary	Safety results	Number of adverse events	Up to 2 years
Secondary	PK	The maximum concentration (Cmax)	Up to 2 years
Secondary	PK	the time to reach the maximum concentration (Tmax)	Up to 2 years
Secondary	PK	The area under the curve (auc0-28d ) at 28d respectively after administration	Up to 2 years
Secondary	PD	Absolute value of CD7 Positive Cells in peripheral blood at each time point	Up to 2 years
Secondary	PD	The proportion of CD7 Positive Cells in peripheral blood at each time point	Up to 2 years
Secondary	ORR	The total response rate was 3 months and 6 months	Up to 2 years
Secondary	overall survival (OS)	Time from initiation of CD7 car-t cell therapy to death (for any reason)	Up to 2 years
Secondary	Search Results Featured snippet from the web Duration of response (DOR)	The time from the first assessment of Cr or PR to the first assessment of recurrence or progression of the disease or death from any cause	Up to 2 years
Secondary	Progression-free survival (PFS)	The time from the beginning of treatment with CD7 car-t cells to the first progression of disease or death from any cause	Up to 2 years
Secondary	Immunogenicity	The positive rate of human anti car antibody at each time point	Up to 2 years